Current big players in the RSV vaccine market, GlaxoSmithKline, Johnson & Johnson, and Pfizer, all have large Phase II studies ongoing for their candidates. Credit: Shutterstock

Concerns over the spread of coronavirus have increased as more countries announced COVID-19 cases in March.

Verdict launched a poll on 13 March to study the concerns over the spread of coronavirus and has been tracking the COVID-19 Concern Index since then through the ongoing poll.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The index is based on respondents, who answered that they are very concerned about the spread of COVID-19.

The COVID-19 Concern Index went northwards from 16 March to hit a high on 31 March, with 80% of the respondents expressing a very high concern. The index was at 71.6% on 16 March.

The concern eased in the second week of April, with the index declining to 75% and has been stable since 11 April. The Index reached a low of 71.34% on 07 April, a level that was witnessed three weeks ago, on 18 March.

The analysis is based on a total of 94,548 responses received up to 13 April. The poll is still running and the analysis will be posted periodically.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now